Analyst Price Targets — VTGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 17, 2025 7:21 pm | Andrew Tsai | Jefferies | $0.90 | $0.86 | StreetInsider | Jefferies Downgrades VistaGen Therapeutics (VTGN) to Hold |
| December 17, 2025 3:48 pm | — | Stifel Nicolaus | $1.00 | $0.79 | TheFly | Vistagen downgraded to Hold at Stifel after PALISADE-3 study disappoints |
| November 17, 2025 2:26 pm | Paul Mattheis | Stifel Nicolaus | $12.00 | $4.60 | StreetInsider | Stifel Reiterates Buy Rating on VistaGen Therapeutics (VTGN) |
| July 22, 2022 11:35 am | Andrew Tsai | Jefferies | $6.00 | $4.38 | TheFly | VistaGen Therapeutics downgraded to Hold from Buy at Jefferies |
Latest News for VTGN
NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) breached their fiduciary duties to shareholders.
SAN FRANCISCO, April 28, 2026 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Vistagen Therapeutics, Inc. (NASDAQ: VTGN) investors that the firm is investigating potential legal claims arising from alleged false statements about Vistagen's drug candidate fasedienol. Current shareholders are encouraged to contact the firm.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug Administration (FDA) under its U.S. Investigational New Drug (IND)…
New York, New York--(Newsfile Corp. - April 20, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vistagen Therapeutics, Inc . (NASDAQ: VTGN ) breached their fiduciary duties to shareholders.
VistaGen Therapeutics, Inc. (NASDAQ: VTGN - Get Free Report) crossed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $0.58 and traded as low as $0.5550. VistaGen Therapeutics shares last traded at $0.5604, with a volume of 277,757 shares trading hands. Wall Street Analysts Forecast
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VTGN.
U.S. House Trading
No House trades found for VTGN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.